



**Michael HUFFORD**  
**Co-Founder & CEO**  
**LyGenesis**

Michael Hufford, PhD is the Co-Founder and CEO of LyGenesis, a clinical-stage drug development company whose cell therapies use lymph nodes as bioreactors to grow functioning ectopic organs. He is also the Interim CEO of Morphoceuticals, a startup pioneering the bioelectric reprogramming of biology. An entrepreneur and drug developer, he has over 20 years of experience in the development and regulatory approval of small molecules, biologics, as well as drug delivery technologies. He has designed and executed clinical trials across a wide variety of therapeutic areas, from orphan metabolic diseases to psychiatry and oncology. His philanthropic work includes co-founding Harm Reduction Therapeutics, a nonprofit pharmaceutical company developing low-cost over-the-counter naloxone in the US to help prevent opioid overdose deaths.

Dr. Hufford earned his undergraduate degree with distinction from Purdue University, and his master's and doctoral degrees in clinical psychology from the University of Pittsburgh before completing a Research and Clinical Fellowship in the Department of Psychiatry at Harvard Medical School. He is the author of more than 100 scientific publications, presentations, and OpEds, with multiple issued and pending patents.